|
Synonyms: 5T4FabV13SEAD227A | ABR 214936 | ABR-214936 | ABR214936 | pMB125 | PNU 214936 | PNU-214936 | PNU214936 | TTS-CD2
Compound class:
Antibody
Comment: Anatumomab mafenatox (ABR-214936) is a fusion protein containing an engineered 5T4 Fab moiety fused via the C terminus of the heavy chain to a mutated form of the Staphylococcal enterotoxin A (SEA) superantigen [1]. SEA is secreted by the pathogen and it stimulates a massive MHC class II-T cell receptor-mediated polyclonal T cell activation, which results in the release of large amounts of cytotoxic and proinflammatory cytokines. Anatumomab mafenatox targets the destructive power of SEA to 5T4-expressing tumour cells. The Asp227Ala mutation is the SEA moiety is designed to reduce MHC class II binding affinity so as to reduce killing of MHC class II positive cells.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Immunopharmacology Comments |
| Anatumomab mafenatox is a novel anti-tumour immunotherapy that targets cancer cells that express trophoblast glycoprotein 5T4, but spares normal adult tissues which do not express 5T4 [1]. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Renal cell carcinoma |
Disease Ontology:
DOID:4450 |
Phase 2 clinical immuno-oncology candidate for advanced RCC. | 2 |
